The Role of Speedy/RINGO Protein in Breast Cancer As a Future Biomarker

Overview

Journal Cancer Diagn Progn

Specialty Oncology

Date 2024 May 6

PMID 38707716

Authors

Ozgur Tanriverdi

Aysegul Yildiz

Affiliations

Soon will be listed here.

Abstract

Background/aim: Cyclin-dependent kinases (CDKs) are proteins that require the binding of regulatory subunits called cyclins and play a key role in cell cycle progression and activation. CDKs play a key role in carcinogenesis of many solid malignancies, and inhibition of these proteins has produced anti-cancer effects demonstrated in preclinical studies. This narrative review was conducted to develop a hypothetical approach to determine whether Speedy/RINGO, a protein associated with CDK2, could be a possible predictive factor in breast cancer patients treated with a CDK4/6 inhibitor.

Materials And Methods: A literature search was conducted in PubMed, Web of Science, Medline, and Google Scholars search engines to match the following words: "Speedy/RINGO" or "Spy1" and "CDKs" or "Cyclin-dependent kinases (CDKs)" and "CDK4/6 inhibitors" and "Regulation" and "Molecular" and "Breast cancer" and "Carcinogenesis". Only articles investigating the relationship between the Speedy/RINGO protein and CDKs at the molecular level were included. Literature information was compiled by trying to establish a relationship with our hypothesis question.

Results: Speedy/RINGO is a tightly regulated proto-oncogenic mammalian protein playing important roles in the somatic cell cycle. Studies have emphasized that although it does not have amino acid sequence homology with cyclins, it can activate CDK2. In addition, results showing molecular compensation of CDK4/6 inhibition through CDK2 activation, also showed that CDK2 can predict drug resistance. Another important finding was that overexpressed Speedy/RINGO, during CDK4/6 inhibitor treatment, could strongly activate CDK2, resulting in a negative response to treatment.

Conclusion: Although many predictive factors have been investigated to indicate response to CDK4/6 inhibitors or determine drug resistance, a consensus biomarker has yet to be established. In light of the information obtained from our review, it can be concluded that the Speedy/RINGO protein may have an important role as a predictive biomarker in terms of response to treatment, continuity of treatment and drug resistance in patients treated with CDK4/6 inhibitors.

References

Goel S, DeCristo M, McAllister S, Zhao J . CDK4/6 Inhibition in Cancer: Beyond Cell Cycle Arrest. Trends Cell Biol. 2018; 28(11):911-925. PMC: 6689321. DOI: 10.1016/j.tcb.2018.07.002. View

Chauhan S, Zheng X, Tan Y, Tay B, Lim S, Venkatesh B . Evolution of the Cdk-activator Speedy/RINGO in vertebrates. Cell Mol Life Sci. 2012; 69(22):3835-50. PMC: 11115036. DOI: 10.1007/s00018-012-1050-1. View

Gastwirt R, McAndrew C, Donoghue D . Speedy/RINGO regulation of CDKs in cell cycle, checkpoint activation and apoptosis. Cell Cycle. 2007; 6(10):1188-93. DOI: 10.4161/cc.6.10.4252. View

Dickler M, Tolaney S, Rugo H, Cortes J, Dieras V, Patt D . MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR/HER2 Metastatic Breast Cancer. Clin Cancer Res. 2017; 23(17):5218-5224. PMC: 5581697. DOI: 10.1158/1078-0432.CCR-17-0754. View

Bonelli P, Tuccillo F, Borrelli A, Schiattarella A, Buonaguro F . CDK/CCN and CDKI alterations for cancer prognosis and therapeutic predictivity. Biomed Res Int. 2014; 2014:361020. PMC: 3925518. DOI: 10.1155/2014/361020. View

Golipour A, Myers D, Seagroves T, Murphy D, Evan G, Donoghue D . The Spy1/RINGO family represents a novel mechanism regulating mammary growth and tumorigenesis. Cancer Res. 2008; 68(10):3591-600. DOI: 10.1158/0008-5472.CAN-07-6453. View

Lubanska D, Porter L . The atypical cell cycle regulator Spy1 suppresses differentiation of the neuroblastoma stem cell population. Oncoscience. 2015; 1(5):336-48. PMC: 4278303. DOI: 10.18632/oncoscience.36. View

Zucchi I, Mento E, Kuznetsov V, Scotti M, Valsecchi V, Simionati B . Gene expression profiles of epithelial cells microscopically isolated from a breast-invasive ductal carcinoma and a nodal metastasis. Proc Natl Acad Sci U S A. 2004; 101(52):18147-52. PMC: 539802. DOI: 10.1073/pnas.0408260101. View

Corona S, Generali D . Abemaciclib: a CDK4/6 inhibitor for the treatment of HR+/HER2- advanced breast cancer. Drug Des Devel Ther. 2018; 12:321-330. PMC: 5818877. DOI: 10.2147/DDDT.S137783. View

10.

Dinarina A, Perez L, Davila A, Schwab M, Hunt T, Nebreda A . Characterization of a new family of cyclin-dependent kinase activators. Biochem J. 2004; 386(Pt 2):349-55. PMC: 1134800. DOI: 10.1042/BJ20041779. View

11.

Tian Y, Wan H, Tan G . Cell cycle-related kinase in carcinogenesis. Oncol Lett. 2012; 4(4):601-606. PMC: 3506610. DOI: 10.3892/ol.2012.828. View

12.

Hortobagyi G, Stemmer S, Burris H, Yap Y, Sonke G, Paluch-Shimon S . Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. N Engl J Med. 2016; 375(18):1738-1748. DOI: 10.1056/NEJMoa1609709. View

13.

Wood D, Endicott J . Structural insights into the functional diversity of the CDK-cyclin family. Open Biol. 2018; 8(9). PMC: 6170502. DOI: 10.1098/rsob.180112. View

14.

Goetz M, Toi M, Campone M, Sohn J, Paluch-Shimon S, Huober J . MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer. J Clin Oncol. 2017; 35(32):3638-3646. DOI: 10.1200/JCO.2017.75.6155. View

15.

Ferraiuolo R, Tubman J, Sinha I, Hamm C, Porter L . The cyclin-like protein, SPY1, regulates the ERα and ERK1/2 pathways promoting tamoxifen resistance. Oncotarget. 2017; 8(14):23337-23352. PMC: 5410308. DOI: 10.18632/oncotarget.15578. View

16.

Fifield B, Qemo I, Kirou E, Cardiff R, Porter L . The atypical cyclin-like protein Spy1 overrides p53-mediated tumour suppression and promotes susceptibility to breast tumourigenesis. Breast Cancer Res. 2019; 21(1):140. PMC: 6907270. DOI: 10.1186/s13058-019-1211-3. View

17.

Bonelli M, La Monica S, Fumarola C, Alfieri R . Multiple effects of CDK4/6 inhibition in cancer: From cell cycle arrest to immunomodulation. Biochem Pharmacol. 2019; 170:113676. DOI: 10.1016/j.bcp.2019.113676. View

18.

Niu Y, Xu J, Sun T . Cyclin-Dependent Kinases 4/6 Inhibitors in Breast Cancer: Current Status, Resistance, and Combination Strategies. J Cancer. 2019; 10(22):5504-5517. PMC: 6775706. DOI: 10.7150/jca.32628. View

19.

Patel P, Tsiperson V, Gottesman S, Somma J, Blain S . Dual Inhibition of CDK4 and CDK2 via Targeting p27 Tyrosine Phosphorylation Induces a Potent and Durable Response in Breast Cancer Cells. Mol Cancer Res. 2018; 16(3):361-377. PMC: 5835198. DOI: 10.1158/1541-7786.MCR-17-0602. View

20.

Hochegger H, Takeda S, Hunt T . Cyclin-dependent kinases and cell-cycle transitions: does one fit all?. Nat Rev Mol Cell Biol. 2008; 9(11):910-6. DOI: 10.1038/nrm2510. View